Pure Global
NCT00998010

Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme
Jonsson Comprehensive Cancer Center·Phase 2·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Brain and Central Nervous System Tumors
Drug/Device/Intervention
bortezomib + temozolomide+ radiation therapy
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jonsson Comprehensive Cancer Center
Location
Los Angeles, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Oct 03, 2011
End date
Apr 20, 2018
Enrollment
24 participants
Primary outcome

Overall Survival

Summary

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
 needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
 such as temozolomide, work in different ways to stop the growth of tumor cells, either by
 killing the cells or by stopping them from dividing. Radiation therapy uses high-energy
 x-rays to kill tumor cells. Giving bortezomib together with temozolomide and radiation
 therapy may kill more tumor cells and allow doctors to save the part of the body where the
 cancer started.
 
 PURPOSE: This phase II trial is studying the side effects and how well bortezomib works when
 given together with temozolomide and regional radiation therapy in treating patients with
 newly diagnosed glioblastoma multiforme or gliosarcoma.

ICD-10 classifications
Malignant neoplasm: Overlapping lesion of brain and other parts of central nervous systemMalignant neoplasm: Central nervous system, unspecifiedBenign neoplasm of brain and other parts of central nervous systemMalignant neoplasm of brainSecondary malignant neoplasm of other and unspecified parts of nervous system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00998010
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00998010 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jonsson Comprehensive Cancer Center and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.